This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Injectable L-Carnitine
L-carnitine IM/IV | Carnitor | Carnitine injection
Aliases (7)
Overview
What is Injectable L-Carnitine?
Injectable L-carnitine is the parenteral form of L-carnitine, a quaternary amine derived from lysine + methionine that is the obligate shuttle for long-chain fatty acids across the inner mitochondrial membrane. The IV form (Carnitor / Sigma-Tau) is FDA-approved for primary systemic carnitine deficiency and end-stage renal disease on hemodialysis. The IM/SC compounded form is widely used off-label by weight-loss clinics and med-spas as a fat-loss adjunct, often paired with MIC blends or GLP-1 agonist programs. Not WADA-prohibited, not DEA-scheduled.
Key Benefits
Bypasses the ~14% oral bioavailability ceiling that limits oral L-carnitine — IM/IV achieves near-100% bioavailability, allowing lower total dose. Real value in (1) FDA-approved indications (PCD, ESRD), (2) acute valproate toxicity, and (3) clinic-mediated weight-loss programs where the injection ritual + clinic engagement drives adherence to caloric deficit. For the healthy-young-athlete archetype: the oral form covers >95% of legitimate use cases at ~1/100th the cost; the injectable rationale is weak.
Mechanism of Action
Oral L-carnitine has ~14-18% bioavailability — most of an oral dose is degraded by gut bacteria into trimethylamine (TMA), which the liver oxidizes to TMAO via FMO3. TMAO is mechanistically tied to atherosclerosis (Koeth 2013 Nature Medicine). Oral remains the standard route for weight-loss meta-analysis evidence (Pooyandjoo 2020) at 1.5-3 g/day; trial efficacy is established but TMAO trade-off is real for chronic use.
Pharmacokinetics
Peptide Interactions
Both support exercise performance via different mechanisms (NO-mediated vasodilation + mitochondrial fatty-acid oxidation). Citrulline 6-8 g pre-workout + L-…
Supports electron transport chain downstream of fatty-acid oxidation. Combined mitochondrial energy support is studied in cardiac and statin-myopathy context…
L-carnitine transports fatty acids including omega-3 EPA/DHA into mitochondria; combination plausibly increases CPT-I activity. Already covered by V4 fish oi…
Antioxidant + mitochondrial cofactor; classic neuropathy-adjacent stack with ALCAR. Oral 600 mg/day is the trial dose; injectable form unnecessary.
Different mechanisms (appetite suppression vs fatty-acid mitochondrial transport); commonly co-administered in clinic weight-loss programs. No direct pharmac…
Redundant carnitine loading. Oral ALCAR + IM L-carnitine produces additive plasma carnitine levels without therapeutic advantage; users get the TMAO bump fro…
Lipo-C in MICC variants already contains 100-200 mg L-carnitine per mL; adding standalone IM L-carnitine duplicates the active component without rationale an…
Same overlap concern as Lipo-C; Fat Blaster contains 300 mg L-carnitine per 1 mL plus MIC + B-complex. Stacking standalone IM L-carnitine doubles up the carn…
Benvenga 2004 documented L-carnitine antagonism of T3/T4 nuclear entry. Therapeutic for hyperthyroid symptom control; problematic for hypothyroid users requi…
Quality Indicators
FDA-Approved Carnitor Vial
Sigma-Tau / Leadiant Carnitor 1 g / 5 mL or 5 g / 25 mL pre-mixed sterile solution, NDC labeled, sealed multi-dose vial. The reference standard for IV/IM L-carnitine.
503A/503B Compounded Vial
PCAB-accredited compounding pharmacy, lot-specific certificate of analysis, sterility + endotoxin testing documented, refrigerated 2-8°C.
Clear Colorless Solution
Properly compounded levocarnitine injection appears as a clear, colorless to slightly yellow solution. No particulates, no cloudiness.
Slight Yellow Tint
Mild yellowing of the solution after light exposure is generally acceptable per USP monograph; persistent or deep amber color suggests degradation.
Cloudiness or Precipitates
Cloudy solution, visible particulates, or crystallization indicates contamination, degradation, or improper storage — discard.
Gray-Market Peptide-Vendor Carnitine
Research-chem peptide vendors selling 'L-carnitine injectable' without sterility/endotoxin documentation are not appropriate for parenteral use. The generic IV form is FDA-approved and available cheaply through legitimate pharmacy channels — gray-market sourcing has no legitimate indication.
What to Expect
- OnsetWithin hours of injection most users report a mild "energy" feeling — typically driven by B-vitamin co-formulations and placebo, not by L-carnitine itself. …
- Off-cyclePlasma carnitine returns to baseline over 1-2 weeks (renal clearance is efficient when sodium-dependent reabsorption is saturated). No withdrawal pattern, n…
Side Effects & Safety 5
Side Effects
- 1Injection-site reactions — mild bruising, stinging, transient soreness; ~30% incidence per Lipo-C pep-pedia community data (n=399). Higher with rapid injection or use of dull needles after multiple doses from the same multi-dose vial.
- 2Bright yellow urine — only with B-vitamin co-formulated blends (riboflavin excretion); pure L-carnitine alone produces no urine color change.
- 3Fishy body odor — when carnitine intake exceeds FMO3's capacity to oxidize TMA → TMAO, residual TMA produces "rotten fish" smell. Less common with IM than oral (since IM bypasses gut bacterial conversion of carnitine to TMA), but still possible at high doses or in FMO3 hypomorphs.
- 4Mild GI upset — nausea, cramping, diarrhea; uncommon at clinic doses, more frequent at high IV protocols (PCD/ESRD).
- 5Headache, restlessness — reported particularly with high IV doses.
When to Stop
- Cardiac arrhythmias — rare reports of increased ventricular arrhythmias in dialysis patients receiving high-dose IV carnitine; signal is small and may be confounded by underlying cardiac disease. Carnitor label flags this.
- Seizure activity — case reports in pre-existing epilepsy patients on chronic L-carnitine of increased seizure frequency; mechanism unclear. The frontmatter hard-blocks seizure history out of caution.
- Allergic reactions — uncommon; document reaction to compounded blends rather than to carnitine itself in most reported cases.
- Hyperthyroid symptom modulation (Benvenga 2004) — L-carnitine 2-4 g/day antagonizes T3/T4 nuclear entry; therapeutic in hyperthyroidism, problematic in hypothyroid patients on replacement. This is documented across multiple trials.
- Day 1 of any new compounding pharmacy lot: check for unusual injection-site reaction (potential preservative or impurity issue).
- Week 1-2 in dialysis patients on IV carnitine: baseline ECG + telemetry monitoring is standard given the rare arrhythmia signal.
- Week 4-6 in clinic weight-loss programs: reassess whether subjective benefit is attributable to carnitine vs concurrent program changes; consider blinded discontinuation trial.
References
Pooyandjoo M, Nouhi M, Shab-Bidar S, et al. 2020 — L-Carnitine for weight loss meta (PMID 31465723)
37-RCT meta-analysis (n=2,292) showing ~1.21 kg weight loss + 2.1 kg fat-mass reduction at oral 1.5-3 g/day.
View StudyHathcock JN, Shao A 2006 — Risk Assessment for Carnitine (PMID 16766096)
Regulatory toxicology review establishing observed safe level (~2 g/day oral).
View StudyBrass EP 2002 — Carnitine in End-Stage Renal Disease (PMID 12500225)
Foundational ESRD review establishing FDA-approved IV carnitine rationale.
View StudyDiNicolantonio JJ, Lavie CJ, Fares H, et al. 2013 — L-Carnitine in Secondary Prevention of CVD (PMID 23597877)
Mayo Clin Proc meta of 13 trials showing post-MI mortality benefit.
View StudyCarnitor (levocarnitine injection) FDA Label
FDA-approved indications, dosing, and pharmacokinetics for IV levocarnitine.
View StudyBain MA, Milne RW, Evans AM 2006 — Disposition and metabolite kinetics of oral L-carnitine (PMID 16638967)
Pharmacokinetic study of ~14-18% oral bioavailability and ~17h plasma half-life.
View StudyKoeth RA, Wang Z, Levison BS, et al. 2013 — Intestinal microbiota metabolism of L-carnitine, atherosclerosis (PMID 23563705)
Nature Medicine TMAO atherogenesis paper.
View StudyKrims-Davis et al. 2025 — Low Bioavailability and High TMAO Production: Novel Insights into Acetylcarnitine and Carnitine Metabolism (Mol Nutr Food Res)
head-to-head ALCAR vs L-carnitine TMAO study.
View StudyLheureux PE, Hantson P 2009 — Carnitine in valproic acid toxicity (PMID 19663038)
Clin Toxicol review establishing IV carnitine antidote protocol.
View StudyTalenezhad N, Mohammadi M, Ramezani-Jolfaie N, et al. 2020 — Effects of l-carnitine on weight loss and body composition (Clin Nutr ESPEN)
companion meta with dose-response identifying 2 g/day optimal.
View StudyBenvenga S, Amato A, Calvani M, Trimarchi F 2004 — Effects of carnitine on thyroid hormone action (PMID 15591020)
Mechanistic + clinical paper on T3/T4 nuclear-entry antagonism.
View StudyWADA 2026 Prohibited List
confirms L-carnitine not prohibited (any route, any form).
View StudyCochrane Review: L-carnitine for acute MI (2018)
more conservative read on cardiac mortality benefit relative to DiNicolantonio.
View StudyHow was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.